[Comment] Subcutaneous IgG for chronic inflammatory demyelinating polyneuropathy

Chronic inflammatory demyelinating polyneuropathy (CIDP) is the most common chronic autoimmune neuropathy and often responds to corticosteroids, plasmapheresis, and intravenous immunoglobulin (IVIg).1 The only US Food and Drug Administration-approved, and the most commonly applied therapy, is IVIg, which, at 2 g/kg followed by 1 g/kg every 3 –4 weeks, has been shown to prevent relapses and maintain stability in 75% of patients.2 Subcutaneous immunoglobulin (SCIg), an alternative route of IgG administration, is approved for IgG replacement therapy in primary immunodeficiency,3 but whether or not it has an effect in balancing immune dys regulation in autoimmune diseases, as IVIg does,4 has not been formally tested.

Source: Lancet Neurology - November 6, 2017 Category: Neurology Authors: Marinos C Dalakas Tags: Comment Source Type: research